Healthcare Testing Services Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Service Type, By Product Type, By Development Stage, By End User, By Region & Competition, 2021-2031F

The Global Healthcare Testing Services Market is projected to expand from USD 6.46 Billion in 2025 to USD 9.01 Billion by 2031, reflecting a CAGR of 5.71%. This sector comprises bioanalytical and analytical testing solutions that medical device manufacturers and pharmaceutical companies utilize to guarantee regulatory compliance, product safety, and quality across the development and manufacturing spectrum. The market's upward trajectory is largely influenced by the growing intricacy of drug molecules, particularly biologics, alongside a strategic pivot toward outsourcing to lower operational expenses. Furthermore, intensified regulatory oversight serves as a crucial growth engine, forcing manufacturers to meet stringent quality benchmarks. This is evidenced by the U.S. Food and Drug Administration's FY2024 Report on the State of Pharmaceutical Quality, which noted 989 drug quality assurance inspections in fiscal year 2024, representing a 27% rise from the prior year.

However, the market encounters a substantial challenge regarding the scarcity of skilled professionals required to manage complex testing methodologies. The limited pool of qualified analysts capable of operating advanced instrumentation and interpreting intricate data sets creates operational bottlenecks and increases labor costs for service providers. This talent gap, exacerbated by the substantial capital investment needed to maintain accredited laboratories, restricts the scalability of operations and could significantly impede the broader expansion of the global healthcare testing sector.

Market Driver

The escalating global prevalence of chronic and infectious diseases acts as a major engine driving the Global Healthcare Testing Services Market. With the rising incidence of complex conditions like diabetes, cancer, and tuberculosis, public health entities and pharmaceutical firms are increasing their requirements for extensive bioanalytical support and diagnostic testing to speed up treatment creation. This necessity is especially urgent for infectious diseases, where rapid surveillance and detection are essential for controlling outbreaks and protecting patient health. As highlighted in the World Health Organization's 'Global Tuberculosis Report 2024' from October 2024, roughly 8.2 million individuals were newly diagnosed with tuberculosis in 2023, marking the highest figure since global monitoring started in 1995. This growing disease burden leads directly to higher volumes of post-market surveillance studies and clinical trial testing needed to verify new therapeutic solutions.

Concurrently, the expansion of R&D pipelines for biologics and biosimilars is transforming the testing services landscape. In contrast to conventional small-molecule drugs, large-molecule therapies such as monoclonal antibodies and cell therapies require highly specialized, sensitive, and expensive analytical testing methodologies to characterize their potency, purity, and immunogenicity. This shift forces manufacturers to outsource these intricate functions to accredited laboratories equipped with advanced instrumentation. According to the Drug, Chemical & Associated Technologies Association, July 2024, in the 'Innovation Scorecard', the U.S. FDA approved 17 new therapeutic biologics in 2023, which represented 31% of all new drug approvals, highlighting the industry's decisive pivot toward complex molecules. The financial magnitude of this sector is evident in the performance of leading service providers; according to Eurofins Scientific, February 2024, in the '2023 Full Year Results', the company reported total revenues of €6,515 million, reflecting the sustained industrial demand for outsourced analytical testing operations.

Market Challenge

A significant barrier impeding the progress of the Global Healthcare Testing Services Market is the shortage of skilled professionals. With medical device and pharmaceutical companies demanding increasingly sophisticated bioanalytical and analytical testing, the sector encounters a severe lack of qualified analysts equipped to handle these advanced techniques. This workforce gap results in operational inefficiencies, such as diminished sample processing capabilities and prolonged turnaround times. Consequently, service providers are compelled to restrict new client acceptance and push back project schedules, which directly inhibits revenue growth and market expansion initiatives.

Moreover, the substantial expense associated with hiring and keeping specialized personnel adds to the financial strain on testing laboratories. This labor constraint is supported by recent industry statistics. The American Society for Clinical Pathology's 2024 Vacancy Survey revealed that anatomic pathology departments experienced a vacancy rate of 28.5 percent, highlighting the acuteness of the labor shortage in essential testing domains. Such elevated vacancy rates hinder laboratories from maximizing the potential of their advanced infrastructure and instrumentation. Without an adequate workforce to facilitate operational scaling, testing service providers are unable to satisfy the growing global demand, effectively halting the broader advancement of the healthcare testing industry.

Market Trends

The Integration of Artificial Intelligence for Enhanced Diagnostic Precision is revolutionizing laboratory workflows by automating complex image analysis and improving clinical decision-making. Laboratories are increasingly deploying machine learning algorithms to process vast datasets in pathology and radiology, thereby reducing human error and identifying subtle biomarkers that traditional methods might miss. This technological shift is accelerating the commercial availability of smart diagnostic tools and facilitating faster regulatory clearances for software-based medical solutions. According to MedTech Dive, October 2024, in the article 'The number of AI medical devices has spiked in the past decade', the U.S. Food and Drug Administration authorized 221 AI or machine learning-enabled medical devices in 2023, marking a significant increase in the validation of these technologies for clinical use.

Simultaneously, the proliferation of Genomic and Precision Medicine Testing Services is moving the diagnostic focus from broad screening to individualized patient profiling. Distinct from standard bioanalytical testing used for characterizing drug substances, this movement emphasizes the identification of hereditary risks and the direction of targeted therapies for specific patients, especially in prenatal care and oncology. In response, service providers are broadening their offerings to encompass advanced molecular diagnostics that provide profound clinical insights and enable personalized treatment strategies. This strong demand is reflected in recent financial performance; Quest Diagnostics, in its 'Fourth Quarter and Full Year 2023 Financial Results' from February 2024, announced double-digit revenue growth in its advanced clinical segments, particularly hereditary genetics and prenatal testing, highlighting the market's uptake of specialized precision testing.

Key Market Players

• Eurofins Scientific (Ireland) Limited
• Thermo Fisher Scientific Inc.
• Microbac Laboratories, Inc.
• ARL Bio Pharma, Inc.
• EM Topco Limited
• Intertek Group plc
• Moderna, Inc.
• ZYUS Life Sciences Corp
• Alcami Corporation
• F. Hoffmann-La Roche Ltd

Report Scope

In this report, the Global Healthcare Testing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Healthcare Testing Services Market, By Service Type

• Chemical Testing
• Microbiological Testing
• Toxicology Testing
• Stability Testing
• Others

Healthcare Testing Services Market, By Product Type

• Anti-viral Drugs
• HIV Drugs
• Fertility Drugs
• Anti-diabetic Drugs
• Respiratory Drugs
• Anticoagulants
• Medical Devices
• Pharmaceutical Packaging
• Others

Healthcare Testing Services Market, By Development Stage

• Preclinical
• Clinical
• Manufacturing

Healthcare Testing Services Market, By End User

• Pharmaceutical Industry
• Contract Research Organization
• Others

Healthcare Testing Services Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Healthcare Testing Services Market.

Available Customizations:

Global Healthcare Testing Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).